These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 27862745)

  • 1. Infliximab-induced cutaneous eruption resembling pityriasis rubra pilaris in a patient with Takayasu's arteritis.
    Salman A; Sonmez Y; Sahin H; Unal AU; Direskeneli H; Cinel L; Ergun T
    Dermatol Ther; 2017 May; 30(3):. PubMed ID: 27862745
    [No Abstract]   [Full Text] [Related]  

  • 2. Pityriasis rubra pilaris-like eruption associated with the multikinase inhibitor ponatinib.
    Jack A; Mauro MJ; Ehst BD
    J Am Acad Dermatol; 2013 Nov; 69(5):e249-e250. PubMed ID: 24124847
    [No Abstract]   [Full Text] [Related]  

  • 3. Pityriasis rubra pilaris-like eruption following administration of the BNT163b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine.
    Hunjan MK; Roberts C; Karim S; Hague J
    Clin Exp Dermatol; 2022 Jan; 47(1):188-190. PubMed ID: 34379821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sofosbuvir-Induced Erythrodermic Pityriasis Rubra Pilaris-Like Drug Eruption.
    Cheung EJ; Jedrych JJ; English JC
    J Drugs Dermatol; 2015 Oct; 14(10):1161-2. PubMed ID: 26461830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythrodermic pityriasis rubra pilaris: Dramatic response to infliximab therapy.
    Karadag AS; Kavala M; Ozlu E; Ozkanlı S; Zindancı İ; Turkoglu Z
    Indian J Dermatol Venereol Leprol; 2016; 82(1):112. PubMed ID: 26728835
    [No Abstract]   [Full Text] [Related]  

  • 6. Pityriasis Rubra Pilaris-Like Reaction Induced by a Tyrosine Kinase Inhibitor, the Ponatinib.
    Mongereau M; Hillion B; Fouillard L; Boivin JF; Gaudron S
    Am J Dermatopathol; 2021 May; 43(5):394-395. PubMed ID: 33264130
    [No Abstract]   [Full Text] [Related]  

  • 7. Pityriasis rubra pilaris-like reaction induced by imatinib.
    Plana A; Carrascosa JM; Vilavella M; Ferrandiz C
    Clin Exp Dermatol; 2013 Jul; 38(5):520-2. PubMed ID: 23777493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib-induced eruption resembling pityriasis rubra pilaris.
    Paz C; Querfeld C; Shea CR
    J Am Acad Dermatol; 2011 Aug; 65(2):452-453. PubMed ID: 21763585
    [No Abstract]   [Full Text] [Related]  

  • 9. [Telaprevir-induced pityriasis rubra pilaris].
    Schmutz JL; Trechot P
    Ann Dermatol Venereol; 2013 May; 140(5):414-5. PubMed ID: 23663723
    [No Abstract]   [Full Text] [Related]  

  • 10. [A new case of pityriasis rubra pilaris-like eruption associated with ponatinib, a tyrosine kinase inhibitor].
    Krygier J; Leemans G; Forsyth R; de Becker A; Gutermuth J; Grosber M
    Ann Dermatol Venereol; 2018 Nov; 145(11):665-670. PubMed ID: 29903676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of pityriasis rubra pilaris (type 1) under combination of infliximab and methotrexate.
    Barth D; Harth W; Treudler R; Simon JC
    J Dtsch Dermatol Ges; 2009 Dec; 7(12):1071-4. PubMed ID: 19689446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pityriasis rubra pilaris: evolution of challenges in promising treatment options.
    Sehgal VN; Srivastava G; Verma P
    Skinmed; 2012; 10(1):18-23. PubMed ID: 22324172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pityriasis rubra pilaris with focal acantholytic dyskeratosis during treatment with imiquimod 5% cream].
    Gómez-Moyano E; Crespo-Erchiga A; Vera Casaño A; Sanz Trelles A
    Actas Dermosifiliogr; 2010 Dec; 101(10):898-900. PubMed ID: 21159271
    [No Abstract]   [Full Text] [Related]  

  • 14. Acantholytic pityriasis rubra pilaris associated with topical use of imiquimod 5%: case report and literature review.
    Leite OG; Tagliolatto S; Souza EM; Cintra ML
    An Bras Dermatol; 2020; 95(1):63-66. PubMed ID: 31789270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dermatomyositis with a pityriasis rubra pilaris-like eruption: an uncommon cutaneous manifestation in dermatomyositis.
    Polat M; Lenk N; Ustün H; Oztaş P; Artüz F; Alli N
    Pediatr Dermatol; 2007; 24(2):151-4. PubMed ID: 17461814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drugs associated with development of pityriasis rubra pilaris: A systematic review.
    Mufti A; Lytvyn Y; Maliyar K; Sachdeva M; Yeung J
    J Am Acad Dermatol; 2021 Apr; 84(4):1071-1081. PubMed ID: 32687965
    [No Abstract]   [Full Text] [Related]  

  • 17. Successful treatment of type I adult-onset pityriasis rubra pilaris with infliximab.
    Manoharan S; White S; Gumparthy K
    Australas J Dermatol; 2006 May; 47(2):124-9. PubMed ID: 16637810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pityriasis rubra pilaris occurring after vaccination with diphtheria-pertussis-tetanus and oral poliovirus vaccines.
    Mohamed M; Belhadjali H; Hammedi F; Ben Meriem C; Zili J
    Indian J Dermatol Venereol Leprol; 2015; 81(6):618-20. PubMed ID: 26515846
    [No Abstract]   [Full Text] [Related]  

  • 19. Pityriasis rubra pilaris treated with methotrexate resolving with an erythema gyratum repens-like appearance.
    Marchetti MA; Greer KE
    J Am Acad Dermatol; 2013 Jul; 69(1):e32-3. PubMed ID: 23768305
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term infliximab treatment for refractory type III juvenile pityriasis rubra pilaris.
    Dessinioti C; Vergou T; Moustou E; Katsambas A; Antoniou C
    Eur J Dermatol; 2011; 21(4):599-600. PubMed ID: 21518691
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.